{"columns":["class_id","label","mechanism","role"],"rows":[["GLP1_SA","Short acting GLP-1 receptor agonist (injectable)","GLP-1 receptor agonist; exenatide twice daily and lixisenatide (half life about 2 to 4 hours); beinaglutide (recombinant human GLP-1; half life of minutes)","intervention"],["GLP1_LA","Long acting GLP-1 receptor agonist (injectable)","GLP-1 receptor agonist; daily or weekly (liraglutide; dulaglutide; semaglutide; exenatide extended release; albiglutide; efpeglenatide; loxenatide; taspoglutide and others)","intervention"],["GLP1_ORAL_PEP","Oral peptide GLP-1 receptor agonist","Oral semaglutide with absorption enhancer","intervention"],["GLP1_ORAL_SM","Oral small molecule GLP-1 receptor agonist","Nonpeptide GLP-1 receptor agonist (orforglipron; danuglipron; lotiglipron; aleniglipron and others)","intervention"],["GIP_GLP1","GIP and GLP-1 receptor co-agonist","Dual incretin agonist (tirzepatide and others)","intervention"],["GCG_GLP1","Glucagon and GLP-1 receptor co-agonist","Dual agonist (survodutide; mazdutide; cotadutide; efinopegdutide; pemvidutide)","intervention"],["GLP1_GLP2","GLP-1 and GLP-2 receptor co-agonist","Dual agonist (dapiglutide)","intervention"],["TRIPLE","GIP; GLP-1 and glucagon receptor tri-agonist","Triple agonist (retatrutide; efocipegtrutide; UBT251 and others)","intervention"],["AMY_GLP1","Amylin and GLP-1 combination or co-agonist","Amylin analogue co-formulated with a GLP-1 receptor agonist (cagrilintide with semaglutide) or unimolecular amylin and GLP-1 agonist (amycretin)","intervention"],["GIPR_ANT_GLP1","GIP receptor antagonist and GLP-1 receptor agonist","Antibody peptide conjugate (maridebart cafraglutide)","intervention"],["INS_GLP1_FRC","Fixed ratio combination of basal insulin and GLP-1 receptor agonist","IDegLira; iGlarLixi; IcoSema","intervention"],["PLACEBO","Placebo","Matched placebo on top of the background therapy shared by all arms","comparator"],["STANDARD_CARE","Standard care or no added treatment","Open label continuation of background therapy without placebo","comparator"],["LIFESTYLE","Lifestyle intervention","Structured diet or exercise program delivered as a randomized arm (not as background shared by all arms)","comparator"],["MET","Metformin","Biguanide","comparator"],["SU","Sulfonylurea","Insulin secretagogue","comparator"],["TZD","Thiazolidinedione","PPAR gamma agonist","comparator"],["DPP4I","DPP-4 inhibitor","Dipeptidyl peptidase 4 inhibitor","comparator"],["SGLT2I","SGLT2 inhibitor","Sodium glucose cotransporter 2 inhibitor","comparator"],["AGI","Alpha glucosidase inhibitor","Acarbose; miglitol; voglibose","comparator"],["GLINIDE","Meglitinide","Repaglinide; nateglinide","comparator"],["UNCLASSIFIED","Mechanism to be verified","Agent whose receptor profile is verified at first inclusion and then reassigned","intervention"],["INS_BASAL","Basal insulin","Insulin glargine; detemir; degludec; icodec; NPH","comparator"],["INS_PRANDIAL","Prandial insulin","Rapid acting insulin analogues or regular insulin at meals","comparator"],["INS_PREMIX","Premixed insulin","Biphasic insulin","comparator"],["AOM_OTHER","Other anti obesity medication","Orlistat; phentermine and topiramate; naltrexone and bupropion; setmelanotide; sibutramine; lorcaserin","comparator"],["SURGERY","Bariatric or metabolic surgery","Any bariatric or metabolic procedure randomized against a node of interest","comparator"],["OTHER_ACTIVE","Other active comparator","Any other active drug or procedure randomized against a node of interest","comparator"]]}